Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock through a trust, according to a recent SEC Form 4 filing.

Summary

• Michael Benkowitz, the President and COO of United Therapeutics, executed stock options and sold shares of common stock on November 6 and 7, 2024.
• The transactions were conducted through trusts where Benkowitz is either a beneficiary and co-trustee with his spouse, or has sole investment and voting power.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
• On November 6, 2024, Benkowitz exercised options to acquire 4,500 shares at $120.26 and 3,000 shares at $102.11, and sold shares at prices ranging from $391.70 to $397.99.
• On November 7, 2024, Benkowitz exercised options to acquire 11,250 shares at $102.11 and 3,750 shares at $111, and sold shares at prices ranging from $400.29 to $403.14.
• The sales were executed in multiple trades at varying prices, with weighted average prices reported for each set of transactions.
• Following these transactions, Benkowitz continues to indirectly own shares through the trusts.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Executive stock sales are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1, which are designed to prevent accusations of insider trading. The market typically views these sales in the context of the executive's overall holdings and the company's performance.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are common across the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
• The use of Rule 10b5-1 trading plans is a standard practice among executives to manage their stock sales in a transparent and compliant manner.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the sales mitigates concerns about insider information being used.

Key Dates